Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4556 Gene Editing

Trading 12-23 12:08:34 EST

416.46

-4.56

-1.08%

High423.54	Low412.92	Vol6.01M
Open419.56	D1 Closing421.02	Amplitude2.52%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O53.36M	T/O Rate--	Tradable Shares0.00
P/B1.920966	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":416.46198,"timestamp":1734973713508,"preClose":421.02008,"halted":0,"volume":6005210,"delay":0,"changeRate":-0.010826,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-4.558105,"latestTime":"12-23 12:08:34 EST","open":419.56058,"high":423.54095,"low":412.92258,"amount":53360635.594497,"amplitude":0.025221,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1734987600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":1.920966,"peRate":-4.856305,"turnoverRate":0.011043,"increases":0,"decrements":6,"flats":0,"marketCap":7739725360,"floatMarketCap":7228389200},"requestUrl":"/m/hq/s/BK4556/wiki","defaultTab":"wiki","newsList":[{"id":"2493675167","title":"5 Biotech Breakthrough Stocks to Watch in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2493675167","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493675167?lang=en_us&edition=fundamental","pubTime":"2024-12-23 22:39","pubTimestamp":1734964740,"startTime":"0","endTime":"0","summary":"After a decent first half, the drug and biotech sector saw a major downturn in the second half due to disappointing third-quarter sales and profits, guidance cuts, pipeline setbacks and the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services.Nonetheless, innovation is at its peak for the industry, with key spaces like diabetes/obesity, gene therapy, inflammation and neuroscience attracting investor attention. FDA approvals continued at a rapid pace throughout 2024. The FDA approved 46 drugs , which is in line with the annual average of 45 to 50 approvals. R&D innovation is likely to remain a major focus area in 2025 as well.In this article, we discuss five of the most enthralling biotech breakthrough stocks for those investors who are looking to diversify away from traditional pharmaceuticals. These stocks are Mind Medicine MNMD, Beam Therapeutics BEAM, Arcellx ACLX, Ocugen OCGN and Insmed INSM. These companies have novel pipeline candidate","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/LQ_ww2eZjlMvbiXmaf.EDA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9d995582658bf49e50317a8120603e3e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/5-biotech-breakthrough-stocks-watch-143900028.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","OCGN","LU0053671581.USD","BK4535","LU0320765992.SGD","GAINI","LU0889565916.HKD","INSM","BK4563","LU0109394709.USD","BK4588","BEAM","ACLX","BK4556","BK4585","BK4547","BK4505","BK4139","ODT","BK4568","MNMD"],"gpt_icon":0},{"id":"2493765825","title":"Buy 5 Genomics & Synthetic Biology Stocks Likely to Soar in Short Term","url":"https://stock-news.laohu8.com/highlight/detail?id=2493765825","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493765825?lang=en_us&edition=fundamental","pubTime":"2024-12-23 20:49","pubTimestamp":1734958140,"startTime":"0","endTime":"0","summary":"Genomics companies analyze and interpret genetic information to uncover insights about genetic variations and disease mechanisms and develop tests, therapies and technologies to advance personalized medicine.Companies in synthetic biology, engineer biological systems for practical applications, including pharmaceuticals and agriculture, using genetic engineering and biotechnology techniques to design novel organisms and processes. The promise of curing genetic diseases and extending human lifespan positions these industries for substantial growth.We recommend five small and mid-sized Genomics & Synthetic Biology stocks with a favorable Zacks Rank that are set to skyrocket in near future. These stocks are: CRISPR Therapeutics AG CRSP, Immunocore Holdings plc IMCR, Monte Rosa Therapeutics Inc. GLUE, Rigel Pharmaceuticals Inc. RIGL and Castle Biosciences Inc. CSTL.Pros and Cons of Genomics & Synthetic Biology Space. Genomics enables tailored treatments to individuals based on their geneti","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_9OKqED6rOANF8VtUei37A--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/buy-5-genomics-synthetic-biology-124900313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861559042.SGD","CSTL","BK4196","BK4505","CRSP","BK4139","BK4585","GLUE","RIGL","IMCR","BK4539","BK4588","LU1861558580.USD","BK4556"],"gpt_icon":0},{"id":"2493223932","title":"This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2493223932","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493223932?lang=en_us&edition=fundamental","pubTime":"2024-12-23 00:25","pubTimestamp":1734884700,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics' approved medicine could benefit from government coverage in the U.S.This is a good sign for the biotech's long-term plans.CRISPR Therapeutics should earn many more approvals in the coming years.The company's shares have been southbound for the better part of three years. And despite major regulatory wins since late 2023, the biotech hasn't recovered: The stock is down 23% year to date.Can CRISPR Therapeutics bounce back?","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F800098%2Fphysician-giving-a-high-five-to-a-young-patient.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F800098%2Fphysician-giving-a-high-five-to-a-young-patient.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/12/22/this-beaten-down-biotech-stock-just-got-some-good/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["CRSP","LU1585245621.USD","LU1861558580.USD","IE0009355771.USD","LU2362541513.USD","IE00BJT1NW94.SGD","LU0417517546.SGD","LU2462157665.USD","IE00BZ9MQY76.HKD","LU1035775433.USD","BK4532","LU0061475181.USD","LU0234570918.USD","BK4585","IE00BJJMRZ35.SGD","LU2237438978.USD","LU0289739699.SGD","BK4556","LU0109394709.USD","LU0889565916.HKD","LU0058720904.USD","BK4567","LU0823416689.USD","LU2417539215.USD","SCD","LU1861559042.SGD","VRTX","LU1093756168.USD","LU1093756325.SGD","BK4533","IE00B894F039.SGD","IE00B19Z9Z06.USD","LU0320765992.SGD","LU2362540622.SGD","IE00B19Z9P08.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","LU2362541273.HKD","LU0079474960.USD","LU0566484027.USD","LU1069344957.HKD","LU2324357040.USD","IE00B2B36J28.USD","LU2236285917.USD","IE00BFTCPJ56.SGD","LU1559883803.SGD","VERX","LU2456880835.USD","IE0002141913.USD","LU0256863811.USD"],"gpt_icon":0},{"id":"2493422931","title":"CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing","url":"https://stock-news.laohu8.com/highlight/detail?id=2493422931","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493422931?lang=en_us&edition=fundamental","pubTime":"2024-12-21 01:58","pubTimestamp":1734717498,"startTime":"0","endTime":"0","summary":"JMP Securities analyst Silvan Tuerkcan has maintained their bullish stance on CRSP stock, giving a Buy rating on December 16. Silvan Tuerkcan has g...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-promising-developments-and-positive-outlook-amid-advancements-in-gene-editing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-promising-developments-and-positive-outlook-amid-advancements-in-gene-editing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4585","CRSP","LU1861559042.SGD","BK4139","BK4588","LENZ","BK4556"],"gpt_icon":0},{"id":"2493346473","title":"Intellia Crashes 60% in a Year: How Should You Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2493346473","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493346473?lang=en_us&edition=fundamental","pubTime":"2024-12-21 01:57","pubTimestamp":1734717420,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics, Inc. NTLA has put up a dismal performance in 2024. Shares of the company have plunged 60.4% compared with the industry’s decline of 13.7%. The deterioration was more pronounced in the past five months. The stock has also underperformed the sector and the S&P 500 Index during this time frame.Intellia is a leading clinical-stage gene editing company focused on developing innovative CRISPR-based therapies. While these innovative therapies have been in the spotlight following the FDA approval of a couple of these in late 2023, investors are disappointed by the recently released data from NTLA’s in vivo CRISPR-based therapies.The FDA recently granted Regenerative Medicine Advanced Therapy designation to nex-z for the treatment of hereditary transthyretin  amyloidosis with polyneuropathy .The observed data also depicted favorable trends across multiple markers of cardiac disease progression at month 12 compared to baseline in an AT","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2ZuhDuDie_37lq4aVERX2Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4718122d03716403704541c667907c4e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intellia-crashes-60-play-stock-175700418.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0823416689.USD","BK4585","LU0205194284.USD","LU1917777945.USD","LU0114720955.EUR","LU0012050646.USD","LU0053666078.USD","BK4535","CRSP","LU0289739699.SGD","BK4139","BK4588","BK4198","LU2023250504.SGD","LU1861559042.SGD","LU0320765992.SGD","LU1169589451.USD","IONS","LU1861558580.USD","LU0882574055.USD","LU2362540622.SGD","NTLA","LU2089984988.USD","LU2468319806.SGD","LU0058720904.USD","LU2106854487.HKD","LU0889565916.HKD","IE00BLDYK493.USD","LU1974910355.USD","LU0106261612.USD","BK4556","IE00B64QTZ34.USD","LU0109394709.USD","LU1169590202.USD","LU2362541513.USD","LU2362541273.HKD","REGN","LU0205193047.USD","HAE"],"gpt_icon":0},{"id":"2492441195","title":"1 big new Green Flag for CRISPR Therapeutics' Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2492441195","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492441195?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:30","pubTimestamp":1734701400,"startTime":"0","endTime":"0","summary":"Regulators just gave a gift to one of CRISPR Therapeutics' programs.The program can now progress through the development process faster.Still, it doesn't guarantee that the program will be a success.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801339%2Fscientist-looking-at-microscope-in-lab1.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801339%2Fscientist-looking-at-microscope-in-lab1.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/12/20/1-big-new-green-flag-for-crispr-therapeutics-stock/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["CRSP","BK4109","LU1861559042.SGD","LU2463526074.USD","BK4139","LU1861558580.USD","LENZ","ASH","BK4585","BK4556","BK4588"],"gpt_icon":0},{"id":"2492866074","title":"Press Release: BLUE MOON METALS CLOSES C$30 MILLION IN EQUITY FINANCING WITH LEAD ORDERS FROM HARTREE PARTNERS, WHEATON PRECIOUS METALS AND LNS, AND SIGNS DEFINITIVE AGREEMENTS TO ACQUIRE TWO NORWEGIAN BROWNFIELD COPPER PROJECTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2492866074","media":"Dow Jones","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492866074?lang=en_us&edition=fundamental","pubTime":"2024-12-20 04:31","pubTimestamp":1734640260,"startTime":"0","endTime":"0","summary":"BLUE MOON METALS CLOSES C$30 MILLION IN EQUITY FINANCING WITH LEAD ORDERS FROM HARTREE PARTNERS, WHEATON PRECIOUS METALS AND LNS, AND SIGNS DEFINITIVE AGREEMENTS TO ACQUIRE TWO NORWEGIAN BROWNFIELD COPPER PROJECTS","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430597077.USD","BK4139","BK4017","BK4585","LU0612318385.USD","LU0654597011.USD","GRO","CFA.SI","WPM","BK4578","LU0612318971.USD","LEAD","BLUE","BK4556","EQR","MOON","BK4588","BK4215"],"gpt_icon":0},{"id":"2492517687","title":"Sector Update: Health Care Stocks Mixed Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2492517687","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492517687?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:10","pubTimestamp":1734617403,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Thursday, with the iShares Biotechnology ETF  0.4% lower and The Health Care Select Sector SPDR Fund  marginally higher.Bio-Path Holdings  shares were up past 487% after the company said results from its preclinical trials of BP1001-A showed \"enhanced insulin sensitivity,\" confirming it as a \"potential\" treatment for obesity and metabolic diseases in type 2 diabetes patients.Mesoblast  stock was over 44% higher after the company said the US Food and Drug Administration has approved its mesenchymal stromal cell therapy Ryoncil for steroid-refractory acute graft versus host disease in children 2 months and older, adolescents and teenagers.Sangamo Therapeutics  shares were up over 15% amid a license deal granting Astellas Pharma worldwide rights to its neurotropic adeno-associated virus capsid, STAC-BBB, for neurological disease targets, the companies said. The consideration for the deal includes a $20 million upfront license payment.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4556","BK4139","BK4581","XLV","SGMO","BPTH","MESO","BK4588","BK4585","IBB"],"gpt_icon":0},{"id":"2492258861","title":"Sangamo Shares Rally Premarket on License Deal With Astellas","url":"https://stock-news.laohu8.com/highlight/detail?id=2492258861","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492258861?lang=en_us&edition=fundamental","pubTime":"2024-12-19 19:20","pubTimestamp":1734607200,"startTime":"0","endTime":"0","summary":"Shares of Sangamo Therapeutics rose sharply in premarket trading Thursday after the genetic-medicine company said it inked a potentially lucrative licensing agreement with Japan's Astellas Pharma.Sangamo said it will receive a $20 million upfront license fee from Astellas and will be eligible to earn up to an additional $1.3 billion in licensed target fees and milestone payments under the agreement, along with royalties on sales of products emerging from the deal.The Richmond, Calif., company said the agreement gives Astellas a license to use its novel proprietary capsid, STAC-BBB, for one neurological disease target, with the right to add up to four more targets.Sangamo shares, which closed Wednesday at $2.35, were recently up 23% to $2.90 in premarket trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4556","BK4139","ALPMY","SGMO"],"gpt_icon":0},{"id":"2492149509","title":"Sangamo Grants Capsid License to Astellas for Neurological Disease Targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2492149509","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492149509?lang=en_us&edition=fundamental","pubTime":"2024-12-19 17:09","pubTimestamp":1734599365,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics  has entered into a license deal granting Astellas Pharma worldwide rights to its neurotropic adeno-associated virus capsid, STAC-BBB, for neurological disease targets, the companies said Thursday.The deal covers one neurological disease target with an option to add up to four additional targets.The consideration for the deal includes a $20 million upfront license payment, potential payments of up to $1.3 billion in additional licensed target fees and milestone payments, as well as royalties on sales.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4556","SGMO","BK4139"],"gpt_icon":0},{"id":"2492111727","title":"BRIEF-Sangamo Therapeutics & Astellas Enter Capsid License Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2492111727","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492111727?lang=en_us&edition=fundamental","pubTime":"2024-12-19 15:35","pubTimestamp":1734593731,"startTime":"0","endTime":"0","summary":"Dec 19  - Sangamo Therapeutics Inc    & Astellas Pharma Inc   :   * SANGAMO THERAPEUTICS AND ASTELLAS ANNOUNCE CAPSID LICENSE AGREEMENT TO DELIVER GENOMIC MEDICINES FOR NEUROLOGICAL DISEASES   * SANGAMO THERAPEUTICS INC - ELIGIBLE FOR UP TO $1.3 BILLION IN MILESTONE PAYMENTS   * SANGAMO THERAPEUTICS INC - TO RECEIVE $20 MILLION UPFRONT LICENSE FEESource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","SGMO","BK4556"],"gpt_icon":1},{"id":"2492117126","title":"Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2492117126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492117126?lang=en_us&edition=fundamental","pubTime":"2024-12-19 15:30","pubTimestamp":1734593404,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUABL9X2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SGMO","BK4139","BK4556"],"gpt_icon":0},{"id":"2492171791","title":"Sangamo Therapeutics Inc - to Receive $20 Million Upfront License Fee","url":"https://stock-news.laohu8.com/highlight/detail?id=2492171791","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492171791?lang=en_us&edition=fundamental","pubTime":"2024-12-19 15:30","pubTimestamp":1734593403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA4QVN4G:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","SGMO"],"gpt_icon":0},{"id":"2492122117","title":"Sangamo Therapeutics Inc - Eligible for up to $1.3 Billion in Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2492122117","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492122117?lang=en_us&edition=fundamental","pubTime":"2024-12-19 15:30","pubTimestamp":1734593403,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nTUA4QVN4G:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4556","SGMO"],"gpt_icon":0},{"id":"2492177531","title":"Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2492177531","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492177531?lang=en_us&edition=fundamental","pubTime":"2024-12-19 15:30","pubTimestamp":1734593400,"startTime":"0","endTime":"0","summary":"- Agreement grants Astellas rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets. - Sangamo to receive a $20 million upfront license fee and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across all five potential disease targets, as well as tiered royalties on potential net sales. Under the terms of the agreement, Sangamo is responsible for completing a technology transfer related to the STAC-BBB capsid. Astellas is responsible for all research, preclinical and clinical development, regulatory interactions, manufacturing, and global commercialization of the resulting gene therapy products. Sangamo will receive a $20 million upfront license fee from Astellas and is eligible to earn up to $1.3 billion in additional licensed target fees and milestone payments across the five potential neurology disease targets, as well as tiered mid-t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/apB1cviRLkHGrqF3Uto9tA--~B/aD03NjM7dz0zMDg3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/14e965f1ab27b83ba8932b589223e1c1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/apB1cviRLkHGrqF3Uto9tA--~B/aD03NjM7dz0zMDg3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/14e965f1ab27b83ba8932b589223e1c1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sangamo-therapeutics-astellas-announce-capsid-073000412.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4556","LENZ","MDCO","SGMO","ALPMF","BK4139","ALPMY"],"gpt_icon":0},{"id":"2492167401","title":"Cathie Wood’s ARK Investment buys 116K shares of Beam Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2492167401","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492167401?lang=en_us&edition=fundamental","pubTime":"2024-12-19 09:10","pubTimestamp":1734570611,"startTime":"0","endTime":"0","summary":"20:07 EST Cathie Wood’s ARK Investment buys 116K shares of Beam Therapeutics (BEAM) today Published first on TheFly – the ultimate source for real-...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-116k-shares-of-beam-therapeutics-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-116k-shares-of-beam-therapeutics-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKK","BK4535","BK4544","BK4585","BK4556","LENZ","BK4139","BK4588","BK4505","BEAM"],"gpt_icon":0},{"id":"2492962857","title":"3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492962857","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492962857?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:59","pubTimestamp":1734443940,"startTime":"0","endTime":"0","summary":"Innovation holds the key in the ever-evolving biotech sector, and most companies in this sector are striving to develop a drug or treatment using a breakthrough technology.Biotech companies with promising gene therapies in their portfolio/pipeline have garnered investors’ attention in 2024. Interest in this space renewed following the FDA approval of a few gene therapies toward the end of 2023.Consequently, some pharma/biotech bigwigs scurried for a lucrative catch in the space, either through licensing deals or acquisitions.Gene therapy enables the modification of a patient’s gene to treat or cure the underlying disease. The treatment involves either replacing a disease-causing gene with a healthy copy of the gene or disabling a disease-causing gene that is not functioning properly. A new or modified gene can also be introduced into the patient’s body to help treat a disease.The therapy takes a different approach from traditional drug therapies as it can treat the underlying cause and","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OQmIpr5vwbHDcZeUdtSZeA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a85ded772dcf5689bab3fdbf2b5da21","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OQmIpr5vwbHDcZeUdtSZeA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4a85ded772dcf5689bab3fdbf2b5da21"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-biotech-stocks-promising-gene-135900489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B2B36J28.USD","BK4139","BK4556","LU1861558580.USD","SRPT","VYGR","LU1861559042.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK4585","IE00BFTCPJ56.SGD","BK4588","IE0002141913.USD","IE00BJT1NW94.SGD","CRSP","CTA"],"gpt_icon":0},{"id":"2492934264","title":"2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?","url":"https://stock-news.laohu8.com/highlight/detail?id=2492934264","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492934264?lang=en_us&edition=fundamental","pubTime":"2024-12-17 17:29","pubTimestamp":1734427740,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics stock is way down in 2024, but Wall Street analysts expect a rebound in 2025.Sales of Iovance Biotherapeutics' first FDA-approved treatment are soaring, but the drugmaker still sports a modest valuation.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801126%2Finvestors-evaluating-a-stock-purchase-getty.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F801126%2Finvestors-evaluating-a-stock-purchase-getty.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/12/17/2-growth-stocks-that-could-rocket-higher-in-2025-a/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4556","CRSP","BK4585","BK4139","LU1861558580.USD","BK4588","LU1861559042.SGD"],"gpt_icon":1},{"id":"2492795316","title":"Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2492795316","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492795316?lang=en_us&edition=fundamental","pubTime":"2024-12-17 09:06","pubTimestamp":1734397576,"startTime":"0","endTime":"0","summary":"20:04 EST Cathie Wood’s ARK Investment buys 96.2K shares of Intellia Therapeutics (NTLA) today Published first on TheFly – the ultimate source for ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-96-2k-shares-of-intellia-therapeutics-today?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-96-2k-shares-of-intellia-therapeutics-today?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4544","BK4556","BK4585","BK4535","BK4139","LU1861558580.USD","ARKK","NTLA","LU1861559042.SGD","BK4588"],"gpt_icon":0},{"id":"2492642665","title":"Crispr Therapeutics call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2492642665","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492642665?lang=en_us&edition=fundamental","pubTime":"2024-12-17 04:25","pubTimestamp":1734380708,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Crispr Therapeutics (CRSP) with 5,198 calls trading, 1.3x expected, and implied vol increasing over 3 points to 55....","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-call-volume-above-normal-and-directionally-bullish-17?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-call-volume-above-normal-and-directionally-bullish-17?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4585","CRSP","LU1861559042.SGD","BK4139","BK4588","LENZ","BK4556"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4556","nameEN":"BK4556"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Gene Editing,BK4556,Gene Editing股票,Gene Editing股票老虎,Gene Editing股票老虎国际,Gene Editing行情,Gene Editing股票行情,Gene Editing股价,Gene Editing股市,Gene Editing股票价格,Gene Editing股票交易,Gene Editing股票购买,Gene Editing股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Gene Editing(BK4556),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Gene Editing(BK4556) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction